Metraipolis › archive › dc_acda288bf8b1

Efficacy of different AV7909 dose regimens in a nonclinical model of pulmonary anthrax — Europe PMC PMID:38115181

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/38115181
DOI
10.1080/21645515.2023.2290345
License (as archived)
CC0-1.0
Archived
2026-10-07T11:30:24.250Z
SHA-256 of the archived text
2104ec78a342623ac9269db5a426f50ce56f7e5b19bf070f4820d1fdcbd6adc0
Stable URL of this page
https://metraipolis.com/documento/dc_acda288bf8b1

How to cite

Efficacy of different AV7909 dose regimens in a nonclinical model of pulmonary anthrax — Europe PMC PMID:38115181 — Europe PMC (en), https://europepmc.org/article/MED/38115181 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_acda288bf8b1 (Metraipolis archive dc_acda288bf8b1, sha256 2104ec78a342623ac9269db5a426f50ce56f7e5b19bf070f4820d1fdcbd6adc0)
BibTeX
@misc{dcacda288bf8b1,
  title = {Efficacy of different AV7909 dose regimens in a nonclinical model of pulmonary anthrax — Europe PMC PMID:38115181},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/38115181},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_acda288bf8b1; sha256 2104ec78a342623ac9269db5a426f50ce56f7e5b19bf070f4820d1fdcbd6adc0},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/38115181. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Pulmonary anthrax caused by exposure to inhaled Bacillus anthracis , the most lethal form of anthrax disease, is a continued military and public health concern for the United States. The vaccine AV7909, consisting of the licensed anthrax drug substance AVA adjuvanted with CpG7909, induces high levels of toxin neutralizing antibodies in healthy adults using fewer doses than AVA. This study compares the ability of one- or two-dose regimens of AV7909 to induce a protective immune response in guinea pigs challenged with a lethal dose of aerosolized B. anthracis spores 6 weeks after the last vaccine dose. The results indicated that AV7909 was less effective when delivered as a single dose compared to the two-dose regimen that resulted in dose-dependent protection against death. The toxin neutralizing assay (TNA) titer and anti-PA IgG responses were proportional to the protective efficacy, with a 50% TNA neutralizing factor (NF 50 ) greater than 0.1 associated with survival in animals receiving two doses of vaccine. The strong protection at relatively low TNA NF 50 titers in this guinea pig model supports the exploration of lower doses in clinical trials to determine if these protective levels of neutralizing antibodies can be achieved in humans; however, protection with a single dose may not be feasible.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: Human vaccines & immunotherapeutics, 2023 (prima pubblicazione 2023-12-19).
Identificativi: PMID 38115181 · PMCID PMC10760354 · DOI 10.1080/21645515.2023.2290345.
Parole chiave degli autori: Bacillus anthracis; Vaccine; anthrax; Post-exposure Prophylaxis; Barda.
Descrittori MeSH principali: Bacillus anthracis; Anthrax; Anthrax Vaccines.
Pagina: https://europepmc.org/article/MED/38115181 — https://doi.org/10.1080/21645515.2023.2290345. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-10-07T11:17:30.915Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.